Weight loss drug makers get a lift today after Aetna (AET -0.6%) revises its criteria under...
Nov 21 2012, 10:40 ET
Weight loss drug makers get a lift today after Aetna (AET -0.6%) revises its criteria under which the insurer considers weight reduction medications as "medically necessary" for treatment of obesity. In a Clinical Policy Bulletin revision dated yesterday, AET identified certain medications that have been approved by the FDA for weight reduction which would be covered under its policy: Qsymia, marketed by VIVUS (VVUS +13.2%), Belviq from Arena Pharmaceuticals (ARNA +2.9%), Didrex from Pfizer (PFE +0.1%), Xenical from Roche (RHHBY +0.3) and GlaxoSmithKline's (GSK +0.2%) Alli. Orexigen (OREX +6.5%), although not named in the bulletin, is also higher on the news.